Lilly Offloads Baqsimi To Amphastar While Investing In Mounjaro Head-To-Head Trial

Although Lilly said the glucagon spray’s relatively low sales were not a factor, the pharma may be prioritizing investment on its newer diabetes and weight-loss drug Mounjaro.